Arrowhead Research Corporation (NASDAQ:ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and Chief Executive Officer Christopher Anzalone, Ph.D., will present at two upcoming nanomedicine-focused events at the Copthorne Tara Hotel in London:
  • SMi 6th Annual RNAi, miRNA and siRNA Conference – “Overcoming a key challenge of RNAi Therapeutics: Effective Systemic Delivery of siRNA in Humans” on June 27 at 12:35 p.m. (London time)
  • SMi Pharmaceutical Nanotechnology: Applications & Commercialization Conference – “Building a Diversified Nanomedicine Company” on June 30 at 11:25 a.m. (London time)

John Rossi, Ph.D., Dean of the Graduate School of Biological Sciences at the Beckman Research Institute City of Hope, Associate Director of Laboratory Research at the City of Hope Comprehensive Cancer Center, and co-founder and member of the Scientific Advisory Board of Arrowhead’s majority owned subsidiary, Calando Pharmaceuticals, Inc., also will present at the SMi 6 th Annual RNAi, miRNA and siRNA Conference:
  • “Small RNAs as Triggers for Epigenetic Control of Gene Expression” on June 28 at 9:10 a.m. (London time)
  • Panel Discussion: “Epigenetics in RNAi” on June 28 at 9:30 a.m. (London time)

The RNAi conference will display some of the most promising results achieved in the field of RNAi, from structural determination to specific therapeutic applications, clinical trial considerations and negotiating the regulatory minefield. The pharmaceutical nanotechnology conference, a case study driven event, will address not only the latest scientific developments, but also the know-how required to successfully translate these discoveries and technologies into a commercially successful product.

About Arrowhead Research Corporation

Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.

For more information please visit . To be added to the Company’s email list to receive news directly, please send an email to .

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market, that our financial initiatives will succeed or that we will be able to continue to operate as a going concern. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.

Copyright Business Wire 2010